NYSE:DPLO - Diplomat Pharmacy Stock Price, News & Analysis

$5.32
+0.23 (+4.52 %)
(As of 08/18/2019 04:00 PM ET)
Today's Range
$4.95
Now: $5.32
$5.35
50-Day Range
$4.86
MA: $5.56
$6.15
52-Week Range
$4.17
Now: $5.32
$21.48
Volume755,300 shs
Average Volume736,574 shs
Market Capitalization$403.42 million
P/E Ratio26.60
Dividend YieldN/A
Beta1.06
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. Read More…

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.7928 per share
Book Value$3.95 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$403.42 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.


Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings data on Friday, August, 9th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.01. The business had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a negative return on equity of 4.01% and a negative net margin of 8.93%. The company's revenue was down 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, August, 9th. The company provided earnings per share (EPS) guidance of ($2.69-2.55) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.54). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $4.91 billion.

What price target have analysts set for DPLO?

13 brokerages have issued twelve-month price targets for Diplomat Pharmacy's shares. Their predictions range from $5.50 to $30.00. On average, they expect Diplomat Pharmacy's stock price to reach $10.1250 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

News coverage about DPLO stock has been trending negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Diplomat Pharmacy.

Are investors shorting Diplomat Pharmacy?

Diplomat Pharmacy saw a drop in short interest in July. As of July 15th, there was short interest totalling 8,278,800 shares, a drop of 7.6% from the June 15th total of 8,959,100 shares. Based on an average daily volume of 765,200 shares, the short-interest ratio is currently 10.8 days. Currently, 14.6% of the shares of the company are sold short. View Diplomat Pharmacy's Current Options Chain.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Operating Officer (Age 48)
  • Ms. Terri Anne Powers, VP of Investor Relations

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.25%), Stephens Inc. AR (8.83%), Vanguard Group Inc. (7.64%), JPMorgan Chase & Co. (1.94%), Northern Trust Corp (1.72%) and Invesco Ltd. (1.63%). Company insiders that own Diplomat Pharmacy stock include Atul Kavthekar, Jeffrey G Park, Joel Saban, Kenneth O Klepper, Philip R Hagerman and Shawn Tomasello. View Institutional Ownership Trends for Diplomat Pharmacy.

Which institutional investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Trexquant Investment LP, Wells Fargo & Company MN, Cubist Systematic Strategies LLC, Voloridge Investment Management LLC, Morgan Stanley, Kings Point Capital Management and Comerica Bank. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Atul Kavthekar, Kenneth O Klepper and Philip R Hagerman. View Insider Buying and Selling for Diplomat Pharmacy.

Which institutional investors are buying Diplomat Pharmacy stock?

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Stephens Inc. AR, JPMorgan Chase & Co., BlackRock Inc., Invesco Ltd., D. E. Shaw & Co. Inc., Charles Schwab Investment Management Inc., Vanguard Group Inc. and Renaissance Technologies LLC. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $5.32.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $403.42 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.View Additional Information About Diplomat Pharmacy.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com/.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  668
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: Buy-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel